Company intelligence / Profile preview
Eutilex Co., Ltd.
Seoul, South Koreaeutilex.com ↗
- Ownership
- Public · 263050
- Development stage
- Phase 2
01
Overview
Confirmed third patient's complete response to treatment (CR) by EBViNT in 2022. Completed EBViNT Phase 1 clinical study in 2014 with no side effects and anti-cancer effect confirmation of EBV-positive tumors.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- TCR T Cell TherapyImmunotherapeutics
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
National Cancer CenterUlsan University HospitalSamsung BioLogicsZhejiang Huahai PharmaceuticalsParexel
Beyond the preview
Go deeper on Eutilex Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eutilex Co., Ltd..